The therapeutic potential of somatostatin receptor ligands in the treatment of obesity and diabetes

Expert Opinion on Investigational Drugs

Volumn 12, Issue 9, 2003, Pages 1501-1509

  Boehm, Bernhard O ^a  

^a UNIVERSITY OF ULM   (Germany)

Author keywords

Diabetic complications; Diabetic retinopathy; Insulin resistance; Landreotide; Obesity; Octreotide; Somatostatin; Somatostatin analogues; Type 2 diabetes

Indexed keywords

ANGIOPEPTIN; ANTIDIABETIC AGENT; BIM 23197; BIM 23244; BIM 23926; G PROTEIN COUPLED RECEPTOR; GLUCOSE; GONADORELIN DERIVATIVE; HUMAN MENOPAUSAL GONADOTROPIN; INSULIN; METFORMIN; OCTREOTIDE; PASIREOTIDE; RECEPTOR SUBTYPE; SEX HORMONE BINDING GLOBULIN; SOMATOMEDIN; SOMATOSTATIN DERIVATIVE; SOMATOSTATIN RECEPTOR; SRIF 14; SRIF 28; UNCLASSIFIED DRUG; VAPREOTIDE; VASCULOTROPIN;

CLINICAL TRIAL; DIABETES CONTROL; DIABETES MELLITUS; DIABETIC RETINOPATHY; DISEASE ASSOCIATION; DOSE RESPONSE; DRUG EFFICACY; DRUG POTENCY; DRUG POTENTIATION; DRUG RECEPTOR BINDING; DRUG TARGETING; GLUCONEOGENESIS; HORMONE INHIBITION; HUMAN; HYPERINSULINEMIA; INSULIN RESISTANCE; INSULIN RESPONSE; LIPOGENESIS; METABOLIC SYNDROME X; OBESITY; OVARY POLYCYSTIC DISEASE; PANCREAS ISLET CELL FUNCTION; PATHOGENESIS; REVIEW; SLOW RELEASE FORMULATION; TREATMENT INDICATION;

DIABETES MELLITUS; DIABETIC RETINOPATHY; FEMALE; HUMANS; LIGANDS; METABOLIC SYNDROME X; OBESITY; POLYCYSTIC OVARY SYNDROME; RECEPTORS, SOMATOSTATIN; SOMATOSTATIN;

EID: 0141740217     PISSN: 13543784     EISSN: None     Source Type: Journal    
DOI: 10.1517/13543784.12.9.1501     Document Type: Review

References (70)

1. MOKDAD AH, SERDULA MK, DIETZ WH, BOWMAN BA, MARKS JS, KOPLAN JP: The spread of the obesity epidemic in the United States. 1991-1998. JAMA (1999) 282:1519-1522.
2. KOPELMAN PG: Obesity as a medical problem. Nature (2000) 404:635-643.
3. CALLE EE, THUN MJ, PETRELLI JM, RODRIGUEZ C, HEATH CW: Body-mass index and mortality in a prospective cohort of US adults. N. Engl. J. Med. (1999) 341:1097-1105.
4. CALLE EE, RODRIGUEZ C,WALKER-THURMOND K, THUN MJ: Overweight, obesity, and mortality from cancer in a prospectively studied cohort of US adults. N. Engl. J. Med. (2003) 348:1625-1638.
5. WHO: Obesity - Prevention and Managing the Global Epidemic. WHO, Geneva, Switzerland (1998).
6. KORNER J, ARONNE LJ: The emerging science of body weight regulation and its impact on obesity treatment. J. Clin. Invest. (2003) 111:565-570.
7. REAVEN GM: Pathophysiology of insulin resistance in human disease. Physiol. Rev. (1995) 75(3):473-486.
8. BONADONNA RC, GROOP L, KRAEMER N: Obesity and insulin resistance in humans: a dose response study. Metabolism (1990) 39:452-459.
9. WHO STUDY GROUP: Prevention of Diabetes Mellitus. WHO, Geneva, Switzerland (1994).
10. YORK DA. Lessons from animal models of obesity. Endocrinol. Metab. Clin. North Am. (1996) 25:781-800.
11. MARIN P, RUSSEFFÉ-SCRIVE A, SMITH J, BJORNTORP P: Glucose uptake in human adipose tissue. Metabolism (1988) 36:1154-1164.
12. LILLIOJA S, NYOMBA B, SAAD M et al.: Exaggerated early insulin release and insulin resistance in a diabetes-prone population: a metabolic comparison of Pima Indians and caucasians. J. Clin. Endocrinol. Metab. (1991) 73:866-876.
13. HAFFNER SM, D'AGOSTINO R, SAAD MF et al.: Increased insulin resistance and insulin secretion in non-diabetic African-Americans and Hispanics compared with non-Hispanic whites: the insulin resistance atherosclerosis study. Diabetes (1996) 45:742-748.
14. POSTIC C, BURCELIN R, RENCUREL F et al.: Evidence for a transient inhibitory effect of insulin on GLUT2 expression in the liver: studies in vivo and in vitro. Biochem. J. (1993) 293:119-124.
15. THORENS B, FLIER JS, LODISH HF, KAHN BB: Differential regulation of two glucose transporters in rat liver by fasting and refeeding and by diabetes and insulin treatment. Diabetes (1990) 39:712-719.
16. KNUTSON VP: Proteolytic processing of the insulin receptor beta subunit is associated with insulin-induced receptor down-regulation. J. Biol. Chem. (1991) 266:15656-15662.
17. RAMSAY TG: Fat cells. Endocrinol. Metab. Clin. North Am. (1996) 25:847-870.
18. SIGAL RJ, EL-HASHIMY M, MARTIN BC, SOELDNER JS, KROLEWSKI AS, WARRAM JH: Acute post-challenge hyperinsulinemia predicts weight gain. Diabetes (1997) 46:1025-1029.
19. LESTUNFF C, BOUGNERES P: Early changes in postprandial insulin secretion, not in insulin sensitivity, characterize juvenile obesity. Diabetes (1994) 43:696-702.
20. CAMPFIELD LA, SMITH FJ, MACKIE G et al.: Insulin normalization as an approach to the pharmacological treatment of obesity. Obesity Res. (1995) 3:591S-603S.
21. BRAY GA, TARTAGLIA LA. Medicinal strategies in the treatment of obesity. Nature (2000) 404:672-677.
22. YANOVSKI SZ, YANOVSKI JA: Obesity. N. Engl. J. Med. (2002) 346:591-602.
23. O'RAHILLY SP, NUGENT Z, RUDENSKI AS et al.: Beta-cell dysfunction, rather than insulin insensitivity, is the primary defect in familial Type 2 diabetes. Lancet (1986) 2:360-364.
24. KOSAKE K, KUZUYA T, HAGURA R, YOSHINAGA H: Insulin response to oral glucose load is consistently decreased in established non-insulin dependent diabetes: the usefulness of decreased early insulin response as a predictor of diabetes mellitus. Diabet. Med. (1996) 13:S109-S119.
25. REAVEN GM, HOLLENBECK CB, CHEN YDI: Relationship between glucose tolerance, insulin secretion, insulin action in non-obese individuals with varying degrees of glucose tolerance. Diabetologia (1989) 32:52-55.
26. PIMENTA W, MITRAKOU A, JENSEN T, YKI-JARVINEN H, DAILY G, GERICH J: Insulin secretion and insulin deficiency in people with impaired glucose tolerance. Diabet. Med. (1986) 13:S33-S36.
27. ZIMMET P, WHITEHOUSE S, ALFORD F, CHRISHOLM D: The relationship of insulin response to a glucose stimulus over a wide range of glucose tolerance. Diabetologia (1978) 15:23-27.
28. KLEIN R: The epidemiology of eye disease. In: Textbook of Diabetes (2nd edn). JC Pickup, G Williams (Eds), Blackwell Sciences, Oxford, England (1997) 44:1-44.9.
29. KOHNER EM: Diabetic retinopathy. Br. Med. J. (1993) 307:1195-99.
30. THE DIABETES CONTROL AND COMPLICATIONS TRIAL RESEARCH GROUP: Retinopathy and nephropathy in patients with Type 1 diabetes four years after a trial of intensive therapy. The Diabetes Control and Complications Trial/Epidemiology of Diabetes Interventions and Complications Research Group. N. Engl. J. Med. (2000) 342:381-389.
31. UK PROSPECTIVE DIABETES STUDY (UKPDS) GROUP: Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with Type 2 diabetes (UKPDS 33). Lancet (1998) 352:837-853.
32. CHATURVEDI N, SJOELIE A-K, PORTA M et al.: Markers of insulin resistance are strong risk factors for retinopathy incidence in Type 1 diabetes. Diabetes Care (2001) 24:284-289.
33. GROOP L, OHRO-MELANDER M: The dysmetabolic syndrome. J. Intern. Med. (2001) 250:105-120.
34. ALBERTI K, ZIMMET: Consultation W. Definition, diagnosis and classification of diabetes mellitus and its complications. Part 1: Diagnosis and classification of diabetes mellitus, provisional report of a WHO consultation. Diabet. Med. (1998) 15:539-553.
35. PORETSKY L, CATALDO NA, ROSENWAKS Z, GIUDICE LC: The insulin-related ovarian regulatory system in health and disease. Endocr. Rev. (1999) 20:535-582.
36. GRANT MB, CABALLERO S: Somatostatin analogues as drug therapies for retinopathies. Drugs Today (2002) 38:783-791.
37. LAMBERTS SWJ, DE HERDER WW, HOFLAND LJ: Somatostatin analogs in the diagnosis and treatment of cancer. Trends Endocrinol. Metabol. (2001) 13:451-457.
38. LAMBERTS SWJ, VAN DER LELY AJ, DE HERDER WW, HOFLAND LJ: Drug therapy: octreotide. N. Engl. J. Med. (1996) 334:246-254.
39. JEANRENAUD B: An hypothesis on the aetiology of obesity: dysfunction of the central nervous system as a primary cause. Diabetologie (1985) 28:502-513.
40. SATOH N, OGAWA Y, KATSURA G et al.: Pathophysiological significance of the obese gene product, leptin in ventromedial hypothalamus (VMH)-lesioned rats: evidence for loss of its satiety effect in VMH-lesioned rats. Endocrinology (1997) 138:947-954.
41. BRAY GA, NISHIZAWA Y: Ventromedial hypothalamus modulates fit mobilization during fasting. Nature (1978) 274:900-902.
42. SCHWARTZ MW, WOODS SC, PORTE D, SEELEY RJ, BASKIN DG: Central nervous system control of food intake. Nature (2000) 404:661-671.
43. BRAY GA, GALLAGHER TF: Manifestations of hypothalamic obesity in man: a comprehensive investigation of eight patients and a review of the literature. Medicine (1975) 54:301-333.
44. LUSTIG RH: Hypothalamic obesity: the sixth cranial endocrinopathy. Endocrinologist (2002) 12:210-217.
45. PINTO G, BUSSIERES L, RECASENS C, SOUBERBIELLE JC, ZERAH M, BRAUNER R: Hormonal factors influencing weight and growth pattern in craniopharyngioma. Hormone Res. (2000) 53:163-169.
46. LUSTIG RH, ROSE SR, BURGHEN GA et al.: Hypothalamic obesity in children caused by cranial insult: altered glucose and insulin dynamics, and reversal by a somatostatin agonist. J. Pediatrics (1999) 135:162-168.
47. LUSTIG RH: The neuroendocrinology of obesity. Endocrinol. Metab. Clin. North Am. (2001) 30:765-785.
48. VELASQUEZ-MIEYER PA, BUFFINGTON CK et al.: Primary insulin hypersecretion: a specific and remediable subtype of obesity. 11th International Congress of Endocrinology, Sydney, Australia (2000) P1054 (Abstract).
49. VELASQUEZ-MIEYER PA, COWAN PA, ARHEART KL et al.: Suppression of insulin secretion is associated with weight loss and altered macronutrient intake and preference in a subset of obese adults. Int. J. Obesity (2003) 27:219-226.
50. LUSTIG RH, HINDS PS, RINGWALD-SMITH K et al.: Octreotide therapy of pediatric hypothalamic obesity: A double-blind, placebo controlled trial. J. Clin. Endocrinol. Metab. (2003) 88:2586-2592.
51. CIOTTA L, DE LEO V, GALVANI F, LA MARCA A. CIANCI A: Endocrine and metabolic effects of octreotide, a somatostatin analogue, in lean PCOS patients with either hyperinsulinemia or lean normoinsulinemia. Hum. Reprod. (1999) 14:2951-2958.
52. PRELEVIC GM, GINSBURG J, MALETIC D et al.: The effects of the somatostatin analogue octreotide on ovulatory performance in women with polycystic ovaries. Hum. Reprod. (1995) 10:28-32.
53. GONI MH, MARKUSSIS V, TOLIS G: Octreotide effect on ovarian morphology in insulin-resistant PCOS patients following six-month decapeptyl treatment. Am. J. Reprod. Immunol. (1994) 31:104-111.
54. PIADITIS GP, HATZIIOANIDIS AH, TROVAS GP et al.: The effect of sequential administration of octreotide alone and octreotide/growth hormone simultaneously on buserelin stimulated ovarian steroid secretion in women with polycstic ovary syndrome. Clin. Endocrinol. (1996) 45:595-604.
55. BOEHM BO, LUSTIG RH: Use of somatostatin receptor ligands in obesity and diabetic complications. Baillieres Best Pract. Res. Clin. Gastroenterol. (2002) 16:493-509.
56. FLYVBJERG A: Growth factors and diabetic complications. Diabet. Med. (1970) 7:387-399.
57. ADAMIS AP, MILLER JW, BDERNAL M-T et al.: Increased vascular endothelial growth factor levels in the vitreous of eyes with proliferative diabetic retinopathy. Am. J. Ophthalmol. (1994) 118:445-450.
58. AIELLO LP, AVERY RL, ARRIGG PG et al.: Vascular endothelial growth factor in ocular fluid of patients with diabetic retinopathy and other retinal disorders. N. Engl. J. Med. (1994) 331:1480-1487.
59. BOUCK N: PEDF: anti-angiogenic guardian of ocular function. Trends Mol. Med. (2002) 8:330-334.
60. KONDO T, VICENT D, SUZUMA K et al.: Knockout of insulin and IGF-1 receptors on vascular endothelial cells protect against retinal neovascularization. J. Clin. Invest. (2003) 111:1835-1842.
61. BOEHM BO, LANG G,VOLPERT O et al.: Low level of the natural ocular anti-angiogenic pigment epithelium-derived factor (PEDF) in aqueous humor predicts progression of diabetic retinopathy. Diabetologia (2003) 46:394-400.
62. VAN HAGEN PM, BAARSMA GS, MOOY CM et al.: Somatostatin and somatostatin receptors in retinal diseases. Eunj Endocrinal. (2000) 143s:43-51.
63. WILSON SH, DAVIS MI, CABALLERO S, GRANT MB: Modulation of retinal endothelial cell behaviour by insulin-like growth Factor I and somatostatin analogues: implications for diabetic retinopathy. Growth Hormone 1GFRes. (2001) ll:S53-S59.
64. BOEHM BO, FELDMANN B, LANG GK, LANG GE: Treatment of diabetic retinopathy with lomng-acting somatostatin analogues. In: Octreotide: the NextDecade. SWJ Lamberts (Ed.). BioScientifica, Bristol, England (1999):241-257.
65. GRANTMB, MAMES RN, FITZGERALD C et al.:The elficacy of octreotide in the therapy of severe nonproliferative and early proliferative diabetic retinopathy: a randomized controlled study. Diabetes Care (2000) 23:504-509.
66. BOEHM BO, LANG GK, JEHLE PM, FELDMANN B, LANG GE: Octreotide reduces risk for vitreous hemorrhages and loss of visual acuity in patients with high risk proliferative diabetic retinopathy. Horm. Metab. Res. (2001) 33:300-306.
67. CLEMENS A, KLEVESATH MS, HOFMANN M et al: Octreotide (somatostatin analogue) treatment reduces endothelial cell dysfunction in patients with diabetes mellitus. Metabolism (1999) 48:1236-1240.
68. KUIJPERS RWAM, BAARSMA GS, VAN HAGEN PM: Treatment of cystoid macular edema with octreotide. N. EngL J. Med. (1998) 338:624-626.
69. FERNANDEZ-REAL JM, RICART W: Insulin resistance and chronic cardiovascular inflammatory syndrome. Endocrine Pev. (2003) 24:278-301.
70. LEGRO RS: Polycystic ovary syndrome and cardiovascular disease: a premature association? Endocrine Rev. (2003) 24:302-312.